Results 11 to 20 of about 2,233 (157)

Tezepelumab in patients with allergic and eosinophilic asthma [PDF]

Allergy, 2023
AbstractAsthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade.
Marco Caminati, Roland Buhl, Jonathan Corren, Nicola A. Hanania, Harold Kim, Stephanie Korn, Marek Lommatzsch, Neil Martin, Andrea Matucci, Shuaib M. Nasser, Ian D. Pavord, Christian Domingo   +11 more
core   +9 more sources

Tezepelumab: First Approval

Drugs, 2022
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class human IgG2λ monoclonal antibody that inhibits the action of TSLP. Administered subcutaneously, it is being developed by Amgen and AstraZeneca for the treatment of asthma ...
Sheridan M. Hoy (4897468)
openaire   +3 more sources

Positioning of Tezepelumab in Severe Asthma

Journal of Investigational Allergology and Clinical Immunology, 2023
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress ...
J C, Miralles-López, D, Antolín-Amérigo, I, García-Moguel, J, Domínguez-Ortega, J, Delgado-Romero, S, Quirce   +5 more
openaire   +3 more sources

Cost-effectiveness of tezepelumab in Canada for severe asthma

Journal of Medical Economics, 2023
To assess the cost-effectiveness of tezepelumab as add-on maintenance therapy compared with standard of care (SoC) for the treatment of patients with severe asthma in Canada. A cost utility analysis was conducted using a Markov cohort model with five health states (“controlled asthma”, “uncontrolled asthma”, “previously controlled asthma with ...
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson, Adrian P. Turner   +8 more
openaire   +3 more sources

Tezepelumab (Tezspire)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
CDA-AMC
openaire   +2 more sources

Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma

, 2023
BACKGROUND Mucus plugs in asthmatic airways are associated with airway obstruction and the activity of inflammatory cytokines, specifically interleukin (IL)-5 and IL-13, and they may provide an opportunity for targeted therapy.
Claire Emson (196258), Jane R Parnes (17065603), Samuel Peterson (6370163), Christopher E Brightling (7668680), Janet M Griffiths (17065597), Celeste Porsbjerg (3155544), Lars H Nordenmark (17065591), John D Newell (8107256), Åsa Hellqvist (17065594), Beata Pawlikowska (17065600), Sarah Diver (7724249), Ayman Megally (17065606), Gene Colice (5129612)   +12 more
core   +6 more sources

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps [PDF]

New England Journal of Medicine
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and safety in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps is unknown.We randomly assigned adults with physician-diagnosed, symptomatic,
Brian J, Lipworth, Joseph K, Han, Martin, Desrosiers, Claire, Hopkins, Stella E, Lee, Joaquim, Mullol, Oliver, Pfaar, Ting, Li, Claudia, Chen, Gun, Almqvist, Mary Kay, Margolis, Julie, McLaren, Shankar, Jagadeesh, Jamie, MacKay, Ayman, Megally, Åsa, Hellqvist, Vaishali S, Mankad, Lila, Bahadori, Sandhia S, Ponnarambil   +18 more
openaire   +3 more sources

Achieving clinical and histologic remission with tezepelumab in an adolescent with refractory eosinophilic gastrointestinal disease: A case report [PDF]

JPGN Rep
Abstract Tezepelumab is a human monoclonal antibody that binds to human thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in Type 2 signaling. We describe a 17‐year‐old with a history of eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis who demonstrated response to tezepelumab with both clinical and histologic ...
Newsome D, Sharlin C, Bauer C, Schroeder S.   +3 more
europepmc   +2 more sources

Tezepelumab treatment for allergic bronchopulmonary aspergillosis

Respirology Case Reports, 2023
AbstractAn 82‐year‐old man had been diagnosed with asthma. He experienced repeated exacerbations requiring treatment with a systemic corticosteroid despite being treated with medications including high‐dose fluticasone furoate/umeclidinium/vilanterol, montelukast sodium, and theophylline; treatment with mepolizumab was then initiated.
Hiroaki Ogata, Kachi Sha, Yasuaki Kotetsu, Aimi Enokizu‐Ogawa, Katsuyuki Katahira, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwaki, Makoto Yoshida   +8 more
openaire   +3 more sources

Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

, 2023
Background: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced exacerbations by 56% compared with placebo in adults and adolescents with severe,
Andrew Menzies-Gow, Yasushi Fukushima, Hiroshi Odajima, Tamotsu Ishizuka, Gene Colice, Gillian Hunter, Motohiro Ebisawa, Hiroshi Okada, Sandhia Ponnarambil, Nobuya Hayashi   +9 more
core   +1 more source